Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022

Int J Mol Sci. 2022 Aug 9;23(16):8874. doi: 10.3390/ijms23168874.

Abstract

The terminal phenoxy group is a moiety of many drugs in use today. Numerous literature reports indicated its crucial importance for biological activity; thus, it is a privileged scaffold in medicinal chemistry. This review focuses on the latest achievements in the field of novel potential agents bearing a terminal phenoxy group in 2013-2022. The article provided information on neurological, anticancer, potential lymphoma agent, anti-HIV, antimicrobial, antiparasitic, analgesic, anti-diabetic as well as larvicidal, cholesterol esterase inhibitors, and antithrombotic or agonistic activities towards the adrenergic receptor. Additionally, for selected agents, the Structure-Activity-Relationship (SAR) is also discussed. Thus, this study may help the readers to better understand the nature of the phenoxy group, which will translate into rational drug design and the development of a more efficient drug. To the best of our knowledge, this is the first review devoted to an in-depth analysis of the various activities of compounds bearing terminal phenoxy moiety.

Keywords: adrenergic receptor activity; analgesic activity; anti-HIV activity; anticancer activity; antidiabetic; antimicrobial; drug scaffold; lymphoma; neurological disorder; phenoxy group.

Publication types

  • Review

MeSH terms

  • Anti-Infective Agents* / pharmacology
  • Antineoplastic Agents* / pharmacology
  • Chemistry, Pharmaceutical
  • Drug Design
  • Molecular Structure
  • Structure-Activity Relationship

Substances

  • Anti-Infective Agents
  • Antineoplastic Agents

Grants and funding

This research received no external funding.